BH

Ben Hohl

Chief Financial Officer and Head of Corporate Development

Enliven Therapeutics

Therapeutic Areas

Enliven Therapeutics Pipeline

DrugIndicationPhase
ELVN-001Chronic Myeloid Leukemia (CML)Phase 1b